Changes of plasma cGP/IGF-1 molar ratio with age is associated with cognitive status of Parkinson disease (2020)
Type of ContentJournal Article
- Science: Journal Articles 
Objective: Cognitive impairment is a common feature of Parkinson disease (PD), for which age is a major contributing factor. Insulin-like growth factor-1 (IGF-1) declines with age and contributes to age-related cognitive impairment in PD. Cyclic glycine-proline (cGP) is a metabolite of IGF-1 and normalizes bioavailable IGF-1. Plasma cGP/IGF-1 molar ratio that represents bioactive IGF-1 in circulation, may associate with the cognitive status in PD. Methods: We examined the association of plasma cGP/IGF-1 molar ratio with the cognitive scores or age in PD patients with normal cognition (PD-N, n = 74), mild cognitive impairment (PD-MCI, n = 71), or dementia (PD-D, n = 33), and with the cognitive scores in 23 age-matched healthy controls. Plasma concentrations of IGF-1, IGF binding protein-3, and cGP were evaluated using enzyme-linked immunosorbent assay (ELISA) and high-performance liquid chromatography-mass spectrometry (HPLC-MS), respectively. Results: The cGP/IGF-1 molar ratio was positively correlated with the age of PD-N group, negatively correlated with the age of PD-D group, and not associated with the age of PD-MCI group. Independent of age, the cGP/IGF-1 molar ratio was positively correlated with the cognitive scores of healthy controls, but not in PD groups. Conclusion: Old healthy people with a higher cGP/IGF-1 molar ratio showed better preserved cognition, possibly due to improved IGF-1 function. Increased cGP/IGF-1 molar ratio with age may contribute to cognitive retention in the PD-N group. The absence or reversal of such association with age in the PD-MCI and PD-D groups may indicate the conversion of cognitive status in PD, if confirmed through longitudinal investigations within the individuals with advancing cognitive impairment.
CitationFan D, Pitcher T, Dalrymple-Alford J, MacAskill M, Anderson T, Guan J (2020). Changes of plasma cGP/IGF-1 molar ratio with age is associated with cognitive status of Parkinson disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring. 12(1).
This citation is automatically generated and may be unreliable. Use as a guide only.
ANZSRC Fields of Research32 - Biomedical and clinical sciences::3209 - Neurosciences::320905 - Neurology and neuromuscular diseases
32 - Biomedical and clinical sciences::3202 - Clinical sciences::320208 - Endocrinology
52 - Psychology::5202 - Biological psychology::520203 - Cognitive neuroscience
52 - Psychology::5202 - Biological psychology::520205 - Psychopharmacology
52 - Psychology::5201 - Applied and developmental psychology::520106 - Psychology of ageing
RightsCopyright 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Showing items related by title, author, creator and subject.
Supplementation of blackcurrant anthocyanins increased cyclic glycine-proline in the cerebrospinal fluid of parkinson patients: Potential treatment to improve insulin-like growth factor-1 function Fan D; Alamri Y; Liu K; Macaskill M; Harris P; Brimble M; Prickett T; Menzies O; Laurenson A; Anderson T; Guan J; Dalrymple-Alford, John (MDPI AG, 2018)Background: Insulin-like growth factor-1 (IGF-1) function is impaired in Parkinson disease. Cyclic glycine-proline (cGP), a metabolite of IGF-1, is neuroprotective through improving IGF-1 function. Parkinson disease patients ...
Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability Botía J; Nalls MA; Noyce AJ; Nicolas A; Cookson MR; Bandres-Ciga S; Gibbs JR; Hernandez DG; Singleton AB; Reed X; Leonard H; Blauwendraat C; Faghri F; Bras J; Guerreiro R; Tucci A; Kia DA; Houlden H; Plun-Favreau H; Mok KY; Wood NW; Lovering R; R’Bibo L; Rizig M; Chelban V; Trabzuni D; Tan M; Morris HR; Middlehurst B; Quinn J; Billingsley K; Holmans P; Kinghorn KJ; Lewis P; Escott-Price V; Williams N; Foltynie T; Brice A; Danjou F; Lesage S; Corvol JC; Martinez M; Giri A; Schulte C; Brockmann K; Simón-Sánchez J; Heutink P; Gasser T; Rizzu P; Sharma M; Shulman JM; Robak L; Lubbe S; Mencacci NE; Finkbeiner S; Lungu C; Scholz SW; Gan-Or Z; Rouleau GA; Krohan L; van Hilten JJ; Marinus J; Adarmes-Gómez AD; Bernal-Bernal I; Bonilla-Toribio M; Buiza-Rueda D; Carrillo F; Carrión-Claro M; Mir P; Gómez-Garre P; Jesús S; Labrador-Espinosa MA; Macias D; Vargas-González L; Méndez-del-Barrio C; Periñán-Tocino T; Tejera-Parrado C; Diez-Fairen M; Aguilar M; Alvarez I; Boungiorno MT; Carcel M; Pastor P; Tartari JP; Alvarez V; González MM; Blazquez M; Garcia C; Suarez-Sanmartin E; Barrero FJ; Rezola EM; Yarza JAB; Pagola AG; de Munain Arregui AL; Ruiz-Martínez J; Cerdan D; Duarte J; Clarimón J; Dols-Icardo O; Reynolds, Regina (Springer Science and Business Media LLC, 2019)Parkinson’s disease (PD), with its characteristic loss of nigrostriatal dopaminergic neurons and deposition of α-synuclein in neurons, is often considered a neuronal disorder. However, in recent years substantial evidence ...
Melzer TR; Stark MR; Keenan RJ; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Grenfell S; Horne KL; Young BN; Pascoe MJ; Almuqbel MM; Wang J; Miller DH; Anderson TJ; Marsh, Steven; Dalrymple-Alford, John (Frontiers Media SA, 2019)The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is unresolved. Here, we used Florbetaben PET ...